Magenta Therapeutics (NASDAQ:MGTA) inks a non-exclusive research and clinical collaboration agreement with Beam Therapeutics (NASDAQ:BEAM)
to evaluate its antibody-drug conjugate (ADC) MGTA-117 for conditioning
sickle cell disease and beta-thalassemia patients receiving the
latter’s base editing therapies.
Conditioning is done to prepare a patient
receiving edited cells that need to engraft in the bone marrow to be
effective. Currently, this is done via chemotherapy or radiation, both
of which are associated with significant toxicities.
MGTA-117 targets only hematopoietic stem and
progenitor cells while sparing immune cells, potentially capable of
clearing space in bone marrow to support long-term engraftment and rapid
recovery.
Under the terms of the partnership, Beam will fund
study costs related to its base editors when combined with MGTA-117 and
Magenta will be responsible for all other development costs related to
the ADC. Each company will retain all commercial rights to their
respective candidates and technologies.
https://seekingalpha.com/news/3582874-magenta-teams-up-beam-therapeutics-in-blood-disorders
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.